HARMONY BIOSCIENCES HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 71.43% for the 12-month period ending 2025-12-31, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2026-08-04
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2025-03-31 was 71.43%, a 1.61% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2024-03-31 was 72.60%.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2022-03-31 was 72.70%.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2024 was 72.98%, a 9.66% decline from fiscal 2023.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2023 was 80.78%, a 4.80% increase from fiscal 2022.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2022 was 77.08%.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2020 was 95.80%, a 3.52% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month |
|---|---|---|---|---|
| 2025-12-31 | 71.43% 10-Q · filed 2026-08-04 | |||
| 2025-09-30 | 71.43% 10-Q · filed 2025-11-04 | |||
| 2025-03-31 | 71.43% 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | 72.98% 10-K · filed 2026-02-24 | |||
| 2024-09-30 | 72.98% 10-Q · filed 2024-10-29 | |||
| 2024-06-30 | 72.98% 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | 72.60% 10-Q · filed 2024-04-30 | |||
| 2023-12-31 | 80.78% 10-K · filed 2026-02-24 | |||
| 2023-09-30 | 80.21% 10-Q · filed 2023-10-31 | |||
| 2023-06-30 | 80.21% 10-Q · filed 2023-08-01 | |||
| 2022-12-31 | 77.08% 10-K · filed 2025-02-25 | |||
| 2022-09-30 | 76.33% 10-Q · filed 2022-11-01 | |||
| 2022-06-30 | 74.99% 10-Q · filed 2022-08-02 | |||
| 2022-03-31 | 72.70% 10-Q · filed 2022-05-03 | |||
| 2020-12-31 | 95.80% 10-K · filed 2023-02-21 | |||
| 2020-09-30 | 95.80% 10-Q · filed 2020-11-12 | |||
| 2019-12-31 | 99.30% 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |